Kardiovaskulære bivirkninger Kardiovaskulære bivirkninger blev rapporteret hos 18, 8% af patienterne i behandlingsperioden.
Cardiovascular reactions Cardiovascular reactions during clinical trials with MabThera monotherapy were reported in 18.8% of patients with the most frequently reported events being hypotension and hypertension.